- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 58 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report
- CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
- CytoSorb, the Wuhan Coronavirus, and Cytokine Storm
- CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin
- CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter
Videos to Watch On The Street - "Cytosorbents CEO on How to Avoid the Flu
and Cytokine Storms" click here
- slider1.jpg
